Wen Z, Liu T, Xu X, Acharya N, Shen Z, Lu Y
Nat Commun. 2025; 16(1):2362.
PMID: 40064918
PMC: 11893787.
DOI: 10.1038/s41467-025-57603-1.
Li L, Zhao L, Zhou D, Yu Y, Zhang P, Zheng J
J Immunother Cancer. 2025; 13(2).
PMID: 40010767
PMC: 11865760.
DOI: 10.1136/jitc-2024-010000.
Gondal M, Cieslik M, Chinnaiyan A
Sci Data. 2025; 12(1):139.
PMID: 39843468
PMC: 11754430.
DOI: 10.1038/s41597-025-04381-6.
Geng Y, Yin T, Li Y, He K, Zou B, Yu J
Mol Carcinog. 2025; 64(4):733-743.
PMID: 39835605
PMC: 11890425.
DOI: 10.1002/mc.23883.
Chen D, Liu P, Lin J, Zang L, Liu Y, Zhai S
Adv Sci (Weinh). 2024; 12(7):e2406624.
PMID: 39739618
PMC: 11831569.
DOI: 10.1002/advs.202406624.
Towards designing improved cancer immunotherapy targets with a peptide-MHC-I presentation model, HLApollo.
Thrift W, Lounsbury N, Broadwell Q, Heidersbach A, Freund E, Abdolazimi Y
Nat Commun. 2024; 15(1):10752.
PMID: 39737928
PMC: 11686168.
DOI: 10.1038/s41467-024-54887-7.
Multi-omics profiling highlights karyopherin subunit alpha 2 as a promising biomarker for prognosis and immunotherapy respond in pediatric and adult adrenocortical carcinoma.
Chen Y, Fang S, Zhong C, Mo S, Shi Y, Ling X
Ann Med. 2024; 56(1):2397092.
PMID: 39624961
PMC: 11616749.
DOI: 10.1080/07853890.2024.2397092.
PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies.
Jin M, Fang J, Peng J, Wang X, Xing P, Jia K
Mol Cancer. 2024; 23(1):266.
PMID: 39614285
PMC: 11605969.
DOI: 10.1186/s12943-024-02176-8.
Construction of a novel lipid drop-mitochondria-associated genetic profile for predicting the survival and prognosis of lung adenocarcinoma.
Cai R, Lin H, Cheng Q, Mao Q, Zhang C, Tan Y
Discov Oncol. 2024; 15(1):668.
PMID: 39551861
PMC: 11570572.
DOI: 10.1007/s12672-024-01526-8.
Unlocking the Secrets of Extracellular Vesicles: Orchestrating Tumor Microenvironment Dynamics in Metastasis, Drug Resistance, and Immune Evasion.
Mir R, Baba S, Elfaki I, Algehainy N, Alanazi M, Altemani F
J Cancer. 2024; 15(19):6383-6415.
PMID: 39513123
PMC: 11540496.
DOI: 10.7150/jca.98426.
A comprehensive investigation of associations between cell death pathways and molecular and clinical features in pan-cancer.
He Y, Wang X
Clin Transl Oncol. 2024; .
PMID: 39487950
DOI: 10.1007/s12094-024-03769-x.
A regularized Cox hierarchical model for incorporating annotation information in predictive omic studies.
Shen D, Lewinger J, Kawaguchi E
BioData Min. 2024; 17(1):44.
PMID: 39449073
PMC: 11515443.
DOI: 10.1186/s13040-024-00398-6.
Integrative multi-omics analysis reveals the role of tumor-associated endothelial cells and their signature in prognosis of intrahepatic cholangiocarcinoma.
Jiang H, Gao B, Meng Z, Wang Y, Jiao T, Li J
J Transl Med. 2024; 22(1):948.
PMID: 39427165
PMC: 11490089.
DOI: 10.1186/s12967-024-05750-2.
Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response.
Lim S, Pires da Silva I, Adegoke N, Lo S, Menzies A, Carlino M
Mol Cancer. 2024; 23(1):228.
PMID: 39394099
PMC: 11468211.
DOI: 10.1186/s12943-024-02146-0.
Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?.
Hossain S, Ly K, Sung Y, Braithwaite A, Li K
Int J Mol Sci. 2024; 25(18).
PMID: 39337605
PMC: 11432671.
DOI: 10.3390/ijms251810120.
Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors.
Malhotra J, De S, Nguyen K, Lee P, Villaflor V
Cancer Immunol Immunother. 2024; 73(11):234.
PMID: 39271499
PMC: 11399531.
DOI: 10.1007/s00262-024-03825-z.
Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade.
Sears T, Pagadala M, Castro A, Lee K, Kong J, Tanaka K
Cancer Immunol Res. 2024; 12(12):1780-1795.
PMID: 39255339
PMC: 11612627.
DOI: 10.1158/2326-6066.CIR-24-0164.
Matrix Metalloproteinase 11 Promotes Migration and Invasion of Colorectal Cancer by Elevating Slug Protein.
Pan C, Dai J, Wei Y, Yang L, Ding Z, Wang X
Int J Med Sci. 2024; 21(11):2170-2188.
PMID: 39239548
PMC: 11373555.
DOI: 10.7150/ijms.98007.
INHBA promotes tumor growth and induces resistance to PD-L1 blockade by suppressing IFN-γ signaling.
Li F, Gu L, Tong Y, Chen R, Chen S, Yu X
Acta Pharmacol Sin. 2024; 46(2):448-461.
PMID: 39223366
PMC: 11747416.
DOI: 10.1038/s41401-024-01381-x.
Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors.
Lim S, Lin Y, Lee J, Pedersen B, Stewart A, Scolyer R
EBioMedicine. 2024; 107:105308.
PMID: 39216232
PMC: 11402938.
DOI: 10.1016/j.ebiom.2024.105308.
